Introduction
Renal cell carcinoma (RCC) comprises about 85% of all tumors which occur in the kidney (Olson et al., 1984) . The incidence of RCC is still increasing throughout the world at an annual rate of 2%. In the United States, this malignancy is diagnosed in more than 27 000 individuals each year, and is responsible for more than 11 000 deaths (Boring et al., 1994) . The etiology has not yet been discerned, however, increased risk to develop RCC is associated with tobacco use, and exposure to environmental carcinogens, such as asbestos. Restrospective analyses of patients undergoing long term kidney dialysis have uncovered an increased frequency of RCC among them. Recent risk assessments estimate these patients have approximately four times the risk of eventually acquiring RCC than the general population (Fallon et al., 1989) .
As most common cancers, RCC occurs in either a sporadic or inherited manner. Histologically, the majority (80 ± 85%) of these tumors are of the nonpapillary, clear cell variety (Kovacs and Ishikawa, 1993) . Clues regarding which genes may be responsible for the initiation and progression of RCC have come from cytogenetic and molecular anlayses performed on both tumor types. Consistent loss of alleles has been detected most frequently on the short arm of chromosome 3 (3p) (Kovacs and Hoene, 1988; Kovacs and Frisch, 1989; Anglard et al., 1991; Morita et al., 1991) . In addition, several families have been identi®ed in which members with constitutional chromosome rearrangements eventually acquire RCC (Cohen et al., 1979; Pathak et al., 1982; Hoene, 1988, 1989; Li et al., 1993) . Cohen et al. (1979) reported one family with ten members who had an apparently balanced t(3;8)(p14.2;q24.1) chromosome translocation, and all of whom developed RCC in their third decade of life. Follow up studies of several of these family members, revealed eventual loss of the derivative chromosome 8 containing genetic material from the 3p14 to terminal region, as their disease progressed .
Comparative hybridization analyses performed on non-metastatic, non-papillary clear cell RCC's, have revealed that a signi®cant portion of 3p is deleted from the 3p14.2 breakpoint of the 3;8 RCC familial translocation, extending through the terminal region of 3p, including the Von ± Hippel ± Lindau (VHL) locus at 3p25 (Moch et al., 1996) . A strong association exists between the manifestation of VHL, an autosomal dominant disorder, with the development of RCC, since 57% of clear cell RCC's show mutations of the VHL gene (Kovacs et al., 1991; Moch et al., 1996) .
In a search for the candidate tumor suppressor gene for RCC, the 3p14.2 locus has been intensively studied (Yamakawa et al., 1992; Boghosian-Sell and Cannizzaro, 1992; LaForgia et al., 1991 LaForgia et al., , 1993 Atchison et al., 1995; Gnarra et al., 1995, Shi and Cannizzaro, 1996) . Even though multiple markers which span this breakpoint region have been isolated, a gene has yet to be identi®ed in RCC, with altered expression as a result of the 3;8 rearrangement. One cDNA clone, HCRA1, was identi®ed which mapped adjacent to the 3;8 translocation, but is not rearranged or expressed in RCC patients (Boldog et al., 1993; Wilke et al., 1994) . A second gene, FHIT, has been mapped by hybridization to markers from within the t(3;8) RCC breakpoint to the 3p14.2 region. This gene is interrupted by the translocation breakpoint region, and portions of it are deleted in esophageal, colon, lung and breast tumors Sozzi et al., 1996; Negrini et al., 1996) . However, the prototypic FHIT gene, isolated from fetal brain and colon cDNA libraries, was not altered in two cell lines and two uncultured renal cell carcinomas established from patients with the sporadic form of RCC . In addition, the mutations of FHIT observed so far in multiple tumor types other than kidney, have not revealed any speci®c pattern in association with the type or stage of malignant progression of these tumors.
Our laboratory has cloned an alternatively spliced version of the FHIT gene from a kidney cDNA library. This gene contains an additional 94 bp exon not found in colon and fetal brain FHIT cDNA . Sequencing analyses of the kidney FHIT reveals that the novel 94 bp sequence maps between exon 2 and exon 3, and is designated as Exon 2a (E2a).
RT ± PCR analyses performed on normal kidney tissues and cell lines demonstrates the presence of exon 2a in all of them. RT ± PCR analyses show loss of the exon 2a in a familial RCC cell line which contains a t(3;8)(p14.2;q24.1) translocation, as well as, in a metastatic tumor derived from a patient with the sporadic form of RCC. In addition, almost 60% of the RCC sporadic tumors and cell lines, show loss of exon 8 from the translated region of the kidney FHIT. Northern expression studies with an exon 2a probe detected the loss of a major 4.4 kb transcript in the familial RCC and in the metastatic RCC tumor, suggesting that the exon 2a sequence may be a potential RCC tumor suppressor site which is positioned on the 5' side of the familial RCC 3;8 chromosome translocation breakpoint region. Thus, these studies provide strong evidence that the exon 2a sequence and the FHIT gene may play an important role in the oncogenesis of renal cell carcinoma.
Results
Mapping a cosmid contig to the t(3;8) breakpoint bȳ uorescence in situ hybridization
Fluorescence in situ hybridizations (FISH) were performed on metaphase chromosomes from the RCC cell line, 9944, established from a family member with the t(3;8)(p14.2;q24.1) translocation, to determine the position of each cosmid of a four cosmid contig: 1B7, 4H6, 6H8 and 1C12, in relation to the translocation breakpoint. Two of the cosmids, 1B7 and 1C12, which mapped to the distal and proximal side of the contig, were labeled with biotin by nick translation and used as probes. Signals were detected on the short arm of both the normal and derivative chromosome 3, as well as, on the long arm of the derivative chromosome 8, which contains the 3p14.2 to the 3p terminal region. No signal was detected in the normal chromosome 8 (Figure 1 ). These results con®rm that 1B7 and 1C12 span the 3;8 translocation breakpoint region and map to the 3p14.2 side of the translocation.
Cloning of an alternatively spliced FHIT cDNA from a kidney cDNA library
This cosmid contig was then used to select cDNAs from a kidney cDNA library. 1610 7 recombinants of the human kidney cDNA library were PCR ampli®ed using the lambda gt10 forward and reverse primers, then screened with the biotin labeled cosmids on the streptavidin magnetic particles surface. After three rounds of selection, the PCR products were cloned into a plasmid vector and re-screened with the cosmids. Forty-four positive clones were selected, and a partial cDNA of 334 bp was sequenced. A polymerase chain reaction strategy was employed to obtain the remainder of the full length cDNA. Two primers, C-F and C-R, were derived from the 334 bp cDNA. PCR ampli®cations were performed by using these two primers, along with the lambda gt10 forward and reverse primers, to screen the human kidney cDNA library. The resulting PCR products were cloned, then, screened with the PCR products of C-F and C-R. A full length cDNA of 1189 bp in size was obtained from this screening (Figure 2a ). Nucleic acid homology searches of the nonredundant databases were performed using BLAST through the National Center for Biotechnology Information server. An additional 94 bp segment located between the FHIT gene's exon 2 and exon 3 at the centromeric 5' end of the cDNA was detected which was not homologous to any other known sequence (Figure 2a and b). This exon was designated as exon 2a (E2a). The Grail and GeneWork 2.4 programs were used to analyse the cDNA's open reading frame (ORF). Although the cloned cDNA sequence is 94 bp longer than the FHIT gene, the predicted ORF is identical to that of the FHIT gene ( Figure 2a ) .
Analysis of the alternative splicing of the FHIT gene in kidney by RT ± PCR Total RNAs were prepared from normal kidney and RCC tumor tissues, normal kidney and RCC cell lines. Initial RT ± PCR analyses were performed with the primers C1-F and C1-R (Figure 3a) . The PCR products were puri®ed and then used as a template for nested PCR. Primers N-F and N-R were constructed to detect mutations in exons 1 through 6 of the kidney FHIT gene (Figure 3a ). Nested PCR with the N-F/N-R primers resulted in a 475 bp product, which . These results con®rm the loss of the 94 bp/ E2a segment in both the familial RCC, as well as, the metastatic RCC. Primers N2-F and N2-R were constructed to detect alterations between exons 6 and 10 of the translated region of the kidney FHIT (Figure 3a) . After nested (2) the kidney FHIT cDNA with the additional 94 bp E2a sequence, and (1) the FHIT cDNA obtained from colon and fetal brain PCR, a 445 bp PCR product was detected in all normal kidney and RCC tumor tissues and cell lines. In addition, a 376 bp product was detected in the metastatic RCC, A95-50, the sporadic RCC tissues, 96150 and 937, as well as, the sporadic RCC cell lines, ST94, 126, UMRC, RCC-2 and 786-0 (Figure 4b, lanes 4, 6, 10, 15, 16, 17 and 18) . Cloning and sequencing of the 376 bp product revealed a deletion of exon 8 in each of these RCC tumor tissues and cell lines ( Figure  3b ).
Northern blot analysis of the Exon 2a expression
In order to assess the aect, if any, these exon deletions had on the expression of the 94 bp+FHIT transcript in each of these tumors, a 20 bp oligo from the 94 bp segment was used as a probe for Northern blot analyses to normal kidney tissues and cell lines, as well as, kidney tumor tissues and cell lines. Two transcripts were detected by Northerns using the E2a probe, a major transcript at 4.4 kb and a minor transcript at 1.5 kb. The 4.4 kb transcript was expressed in normal kidney tissue and cell line, A94-8 and 346, the sporadic RCC tissue, S95-89, and the sporadic RCC cell line, JD1. However, this 4.4 kb transcript was not expressed in either the familial t(3;8) containing RCC cell line, 9944, or the metastatic RCC tumor tissue, A95-50 ( Figure 5A .1, lanes 4 and 6). It also appears that the expression level of the 1.5 kb transcript is less in the familial and metastatic RCC than the level detected in the normal and abnormal kidney tissues and cell lines which retain the E2a sequence. This dierence in expression level of the 1.5 kb transcript may indicate production of a truncated transcript resulting from the splicing out of the E2a portion of the kidney FHIT.
Since nested PCR analyses revealed that the 94 bp/ E2a sequence is deleted in the familial and metastatic RCC, one can postulate that production of the 4.4 kb transcript is partially a result of the presence of the E2a sequence in the untranslated region of the kidney FHIT cDNA. The deletion of exon 8, on the other hand, does not appear to alter the expression of either the 4.4 kb or the 1.5 kb transcript. However, the splicing out of exon 8 in the translated region of the kidney FHIT cDNA could produce a frameshift mutation shortening the length of the protein sequence which could lead to diminished or altered protein activity.
Additional hybridizations were performed with a FHIT cDNA which did not contain the E2a sequence, to determine which portion of the cDNA was responsible for the expression of the two transcripts. Results of these hybridizations are shown in Figure 5 . Figure 5A .2 demonstrates selective expression of the 1.5 kb transcript in both the normal and RCC kidney tissues and cell lines using the kidney FHIT cDNA without the E2a sequence. Figure 5B .1 is a series of sporadic RCC tissues and cell lines which demonstrate selective expression of the 1.5 kb transcript, again using the FHIT cDNA without the E2a sequence. Figure 5B .2 shows expression of both transcripts in a series of sporadic RCC tissues and cell lines using the kidney FHIT with the E2a sequence. This series of Northerns clearly demonstrates that the 4.4 kb transcript contains the E2a sequence, and that the 
Discussion
An alternatively spliced variant of human FHIT cDNA has been cloned, and has been detected in normal kidney derived tissues, as well as, in sporadic and familial forms of renal cell carcinoma. This alternative form of the FHIT gene contains a novel 94 bp exon, designated exon 2a (E2a), which is located between exon 2 and exon 3. This is the ®rst such documentation of an alternative form of the FHIT gene and this alternatively spliced variant of FHIT has not been detected in the prototypic FHIT cDNA isolated from fetal brain and colon cDNA libraries .
RT ± PCR analyses performed on a series of familial and sporadic RCC tumors demonstrate selective alterations within the kidney FHIT gene. A deletion of the E2a sequence was observed in an RCC cell line derived from a family member with a t(3;8) chromosome rearrangement, as well as, in a metastatic RCC tissue taken from a patient with the sporadic form of RCC.
A high rate of exon 8 deletion was also detected by RT ± PCR analysis in sporadic RCC tumors and cell lines, occurring in almost 60% of these tumors. Previous RT ± PCR analyses of lung and breast tumors have also shown loss of exon 8 in the FHIT cDNA. However, in these tumors, a deletion of exon 8 was usually observed in conjunction with deletions of one or several other exons from the translated region of the prototypic FHIT gene Sozzi et al., 1996) . Since the FHIT gene spans the common fragile site region at 3p14.2, it is not surprising that deletions of dierent portions of FHIT have been found in multiple tumor types. Due to the composition of sequences in fragile sites, the DNA in these regions is considered to be a`hot spot' for mutative events. The discovery of a gene like FHIT which spans a fragile site, may provide information regarding the molecular mechanism responsible for the development of oncogenicity and the progression of events which lead to development of a metastatic lesion. In addition, this discovery may uncover the signi®cance of fragile sites in the genome, a topic of controversy over the last decade. Northern analyses performed with the 94 bp/E2a sequence as a probe, show that a 4.4 kb transcript appears to be the major expression product of the kidney FHIT cDNA, and that the 94 bp/E2a exon is contained within this transcript. Further evidence regarding this is shown by RT ± PCR and Northern studies of familial and metastatic RCC's, where loss of the E2a/94 bp sequence is detected in conjunction with the loss of expression of the 4.4 kb transcript. A promoter sequence 5' to the E2a sequence is the most likely mechanism responsible for regulating the expression of this large 4.4 kb transcript. Since the E2a sequence does contain an internal stop codon, loss of E2a may result in premature termination and ultimate loss of expression of the 4.4 kb transcript. Primers have been constructed to the 5' end of the kidney FHIT and chromosome walking is in progress to isolate an upstream promoter sequence which may be responsible for regulating the E2a portion of the kidney FHIT gene.
We have shown that the kidney FHIT gene is strongly homologous to the colon and fetal FHIT cDNA, but diers signi®cantly due to the alternative splicing represented by the presence of the 94 bp/E2a sequence. Even though the predicted protein sequence of the alternatively spliced FHIT is structurally similar to the prototypic FHIT, it is possible that the protein produced by the alternative form may dier in activity. Interestingly, the splicing out of exon 8 in a large proportion of sporadic tumors does not alter the expression of either the 4.4 kb or the 1.5 kb transcript. Since exon 8 is within the open reading frame (ORF) ± 3) , and the RCC tissues, 1000, 1022 and 1088 (lanes 4 ± 6). A weak signal is detected for the 1.5 kb transcript in all the RCC cell lines and tissues of the FHIT gene, its deletion in RCC tumors would shorten the amino acid sequence as a result of a frameshift mutation, thereby causing an alteration of the 94 bp+FHIT proteins' conformation. Conformational analyses must be undertaken to determine how the FHIT protein is aected by the alternative splicing, as well as, any mutations occurring in either the untranslated/translated portions of the kidney FHIT. Because of the position of the E2a sequence, it is possible that a gene upstream may function in regulating the alternatively spliced variant of the FHIT gene. This as-yet-to-be identi®ed gene along with the alternative variant of FHIT may play a signi®cant role in the development of the transformation of kidney derived cells which leads to manifestation of renal cell carcinoma. Functional analyses are now underway to determine the role the kidney FHIT gene plays in kidney development, as well as, to determine how the E2a sequence contributes to tumor suppressor activity in renal cell carinoma.
Materials and methods

Cosmids, kidney tissues and cell lines
A cosmid contig of four cosmids, designated 1B7, 4H6, 6H8 and 1C12, which covered the t(3;8) translocation breakpoint region at 3p14.2, were used to select cDNAs. Tissues and cell lines used included: normal kidney tissues, A95-8 and 1068 (kindly provided by Dr Howard Ratech); sporadic renal cell carinoma tissues, A95-89, 937, 96150, 1000, 1022 and 1088 (kindly provided by Dr Howard Ratech); oncocytoma tissues, 814 and 906; normal kidney cell line, 346; sporadic RCC cell lines, ST94 126, UMRC, RCC-2 and 786-0 (kindly provided by Dr Robert Burk); a sporadic RCC cell line with a t(3;6) translocation, JD1; a familial RCC cell line, 9944 with a t(3;8) translocation (kindly provided by Drs Robert Gemmill and Frederick Li); and a metastatic RCC tissue, A95-50, established from a patient with a sporadic RCC.
FISH
Fluorescence in situ hybridization (FISH) was performed on metaphase chromosomes obtained from cell line 9944 with the t(3;8)(p14.2;q24.1) translocation to determine the position of each cosmid in relation to the translocation breakpoint. Cosmids were labeled with biotin-14-dATP by nick translation (BioNick Labeling System, Gibco BRL) using chromosome 3 alpha-satellite (D3Z1)(ONCOR) and chromosome 8 alpha-satellite (D8Z2)(ONCOR) to distinguish the normal and derivative chromosomes (Shi and Cannizzaro, 1996) . The hybridization signals were cytochemically detected with FITC-labeled Avidin (ONCOR) and the chromosomes were counterstained with Propidium Iodide (PI)(ONCOR).
Direct cDNA selection, cloning and sequencing
One mg of each cosmid DNA was labeled with biotin (BioNick Labeling System, Gibco BRL) and puri®ed with a G-50 sephadex column (Boehringer Mannheim). The four biotin labeled cosmids were pooled together, denatured at 958C for 5 min after adding KCl to 100 mM ®nal concentration, then annealed to the streptavidin magnetic particles (Promega) at room temperature for 1 h. The particles were washed with 200 ml washing buer containing 100 mM KCl, 1.5 mM MgCl 2 , 10 mM TrisHCl pH 8.6, 5 mM NH 4 Cl at room temperature for 5 min for four times, then, blocked with 50 mg denatured human Cot-I DNA (Gibco BRL), 7.5 mg HeaII digested cosmid vector DNA in 750 mM NaCl, 50 mM NaPO 4 , 56Denhardt's reagent, 0.05% SDS, 5 mM EDTA, and 50% formamide. The particles were then washed with 200 ml washing buer for 5 min at room temperature and, pelleted with a magnet (Promega). 1610 7 recombinants of a human kidney cDNA library (Clontech) were ampli®ed by PCR using lambda gt 10 forward and reverse primers (Sambrook et al., 1989) . The PCR products were puri®ed (PCR Puri®cation Kit, Qiagen), and, denatured at 958C for 5 min after adding 1/ 20 volume of 1 M KCl, chilled on ice for 3 min, then hybridized to the biotin labeled cosmid on the magnetic particles at 658C for 14 h. The particles were washed in 26SSC for 15 min at room temperature, 26SSC for 15 min at 688C, with a ®nal wash in 0.26SSC for 15 min at 688C ®ve times. Speci®c cDNAs were eluted from the particles at 708C for 15 min in 100 ml H 2 O and ampli®ed by PCR. The PCR products were hybridized another two times with the biotin labeled cosmids using the same conditions. The ®nal PCR ampli®ed speci®c cDNAs were cloned into pBluescript plasmid vector (Stratagene) and sequenced with Sequenase Version 2.0 (USB) according to the manufacturer's instructions.
PCR assays
Reactions were performed in 10 mM TrisCl, pH 8.3, 50 mM KCl, 1.5 mM MgCl 2 , 200 mM dNTP mix, 200 nM of each primer, 100 ± 200 ng template DNA and 5 U Taq DNA polymerase in a 100 ml volume. For ampli®cation of human kidney cDNA library and, selected cDNAs, the PCR conditions were: a 3 min denaturation at 938C followed by 10 cycles of denaturation at 938C for 45 s, annealing at 588C for 1 min, extension at 728C for 3 min, followed by another 10 cycles of denaturation at 938C for 45 s, annealing at 588C for 1 min, extension at 728C for 4 min and, a ®nal 8 min extension at 728C. For ampli®cation of the remainder of the full length cDNA and for nested PCR, the PCR conditions were the same as those used for RT ± PCR ampli®cation described below. For ampli®cation of the segment between primers C-F and C-R, the PCR conditions were: a 5 min denaturation at 948C followed by 30 cycles of denaturation at 948C for 30 s, annealing at 568C for 45 s, extension at 728C for 1 min, followed by a ®nal extension at 728C for 8 min. PCR reactions were performed on a Programmable Thermal Control Cycler (MJ Research, Inc). PCR products were analysed by gel electrophoresis using 1.5% agarose. PCR products for cloning were puri®ed using PCR puri®cation columns (Qiagen). Cloning of PCR products was performed with a PCR Cloning Kit (Promega).
PCR primers
Lambda gt10 forward primer, 5'-AGCAAGTTCAGCCTG-GTTAAG-3'; lambda gt10 reverse primer, 5'-CTTATGAG-TATTTCTTCCAGGGTA-3'; C-F: 5'-TACATCCAGAC-GGTGGAAGG-3'; C-R: 5'-GGCTTGATGAGATGTT-GG C-3'; C1-F: 5'-GCTGTCAACATCCTGGAAGC-3'; C1-R: 5'-TCACTGGTTGAAGAATACAGG-3'; N-F: 5'-ATCCT GGAAGCTTTGAAGCTCA-3'; N-R: 5'-ATCAG-GACGCAGGTCATGG-3'; N2-F: 5'-AGGACATGTCCT-TGTGT GCC-3'; N2-R: 5'-TGCTGATTCAGTTCCTCTT-GG-3'. The sequence of the 20 bp oligo probe is 5'-CTGT-AGCC GCTGAAGAGAGG-3'.
Southern blot analyses
Human genomic DNA (Promega) and genomic DNA from cell lines/tissues were isolated with the Genomic DNA Isolation Kit (CLONTECH). DNAs were digested with restriction enzymes, separated on a 0.8% agarose gel, then transferred to Hybond N+ nylon membrane (Amersham) in 0.4 M NaOH, 1.5 M NaCl. Probes were labeled with [ 32 P]dCTP by random priming (Boehringer Mannheim) and, puri®ed with G-50 Sephadex columns (Boehringer Mannheim). Hybridizations were performed at 658C in 0.5 M NaHPO 4 (pH 7.2), 1 mM EDTA, 1% BSA and 7% SDS for 16 h. Filters were washed in 26SSC, 0.1% SDS at room temperature, then in 0.26SSC, 0.1% SDS at 658C two times for 15 ± 20 min each.
Isolation of RNA and Northern analyses
Total RNA was isolated from human kidney tissues and cell lines with TRIzol Reagent (Gibco BRL) (Gramza et al., 1995) . Fifteen to 20 mg were denatured in formamide, then, electrophoresed on a 1% 6M formaldehyde agarose gel (MorthernMAX AMBION). After staining with ethidium bromide to visualize the ribosomal RNA bands, the gels were blotted onto nylon membrane in transfer buer. Oligo-probes were labeled with 32 P by T 4 polynucleotide kinase (Gibco BRL) and puri®ed with G-50 sephadex columns. Hybridization of the Northern blots were carried out according to the manufacturer's instructions.
RT ± PCR analyses
First strand cDNA synthesis was performed at 428C for 30 min under the following conditions: 50 mM Tris HCl, pH 8.3, 75 mM KCl, 3 mM MgCl 2 , 10 mM DTT, 0.5 mM dNTP mix, 1 mM reverse primer, 2 ± 5 mg total RNA and, 200 units SuperScript II Reverse Transcriptase (Gibco BRL) in a total volume of 20 ml. RNA, reverse primers and, H 2 O were mixed, then heated to 708C for 5 min, and chilled on ice prior to the addition of the other ingredients. Eight ml of the ®nal mixture was used in 45 ml volume of PCR. Hot-start PCR was carried out under the following conditions: 1 min denaturing at 948C, 1 min annealing at 558C, 2 min extension at 728C for 35 cycles, and another 10 min extension at 728C.
